Oestrogen and breast cancer: Results from the WHI trial

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 437-438

  Howell, Anthony ^a   Cuzick, Jack ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; PLACEBO;

ADVANCED CANCER; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER SCREENING; DOSE RESPONSE; DRUG MEGADOSE; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; LETTER; MAMMOGRAPHY; PRIORITY JOURNAL; RISK REDUCTION;

BREAST NEOPLASMS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS;

EID: 84860434689     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70110-9     Document Type: Letter

References (10)

1. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012, published online March 7. 10.1016/S1470-2045(12)70075-X.
2. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
3. Genazzani AR, Gadducci A, Gambacciani M Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 2001, 4:181-193.
4. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001, 93:1714-1723.
5. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs. high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer. JAMA 2009, 302:774-780.
6. Dhodapkar MV, Ingle JN, Ahmann DL Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995, 75:43-46.
7. Bhavnani BR, Tam SP, Lu X Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERα and ERβ. Endocrinology 2008, 149:4857-4870.
8. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011, 305:1305-1314.
9. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009, 2:228-239.
10. Taylor HS, Ohleth K Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. Menopause 2012, published online Jan 24. 10.1097/gme.0b013e31823dbbca.